ClinicalTrials.gg
CompletedNCT05332366Updated Mar 6, 2025Results posted

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Frontal Fibrosing Alopecia, sponsored by LEO Pharma. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
117th of 203
35 · median 40
Started
2022
with 16 others
Phase 2
47 of 216
6 open now
Registered
136th of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 117th largest by enrollment of the 203 interventional ones that give a count, is one of 17 that started in 2022, is one of 47 in phase 2, and was the 136th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions. The trial also investigated the clinical effect of delgocitinib cream on FFA compared to a placebo cream.

03

Conditions studied

  • Frontal Fibrosing Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Group 1 only (subjects with FFA):

  1. Male or female subject aged 18 years of age or older at the time of consent.
  2. Subject has clinically confirmed diagnosis of FFA.
  3. Subject has a target area with a perifollicular erythema score ≥ 2 and a perifollicular scale score ≥ 2 at Screening and Day 1.

For Group 2 only (healthy subjects):

  1. Female subject aged 45 years of age or older at the time of consent.
  2. Female is .
  3. Subject is in good general health.

Exclusion criteria

Exclusion criteria

For all subjects:

  1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the trial.
  2. Presence of or C infection or infection at screening.

For Group 1 only (subjects with FFA):

  1. History of other scalp/hair disease including discoid lupus erythematosus and central centrifugal cicatricial alopecia.
  2. Subject who has undergone scalp reduction surgery or hair transplantation.
  3. Subject is known to have immune deficiency or is .
  4. Subject has used intralesional scalp or rich plasma injection in the last 4 weeks prior to randomization.
  5. Subject has used systemic treatment with immunosuppressive/modulating medication or medication within 4 weeks prior to randomization.
  6. Subject has used any topical medicated treatment that could affect FFA within 2 weeks prior to randomization.
  7. Subject has received any phototherapy within 4 weeks prior to randomization.

For Group 2 only (healthy subjects):

  1. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the trial assessments.
  2. Subject has used a topical medicated treatment on the targeted skin sites within 2 weeks prior to trial assessments.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Delgocitinib - Delgocitinib

    Participants were blinded and randomised to delgocitinib cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.

    Drug: Delgocitinib cream

  • Placebo comparator
    Placebo - Delgocitinib

    Participants were blinded and randomised to placebo cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.

    Drug: Delgocitinib cream · Drug: Delgocitinib cream vehicle

  • No intervention
    No treatment

    Participants did not receive any treatment. They only provided a molecular signature of healthy skin to act as a control.

Interventions

  • Cream for topical application

    Also known as: LEO 124249 cream

  • DrugDelgocitinib cream vehicle

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

06

What researchers measure

Primary outcomes

  1. Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.

    CXCL9, CXCL10 and IFN-γ are small proteins that act as chemical messengers, especially in the immune system.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.

    Treatment emergent adverse events (TEAEs) were defined as any AEs with onset date on or after the first study treatment dosing.

    Time frame: Between baseline and Week 12

07

Results

Posted Feb 7, 2025

Participant flow

The trial was conducted in the United States and consisted of 2 cohorts: Cohort 1 included 30 subjects with FFA and Cohort 2 included 5 healthy postmenopausal female subjects. Both cohorts were conducted in parallel.

Participant flow — Overall Study
MilestoneDelgocitinib - DelgocitinibPlacebo - DelgocitinibNo Treatment
Started15155
Completed15155
Not completed000

Outcome measures

PrimaryChange in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.

CXCL9, CXCL10 and IFN-γ are small proteins that act as chemical messengers, especially in the immune system.

Time frame:
Baseline and Week 12
Reported as:
Number · Fold-changes
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.
Fold-changesDelgocitinib - DelgocitinibPlacebo - DelgocitinibNo Treatment
(C-X-C motif) ligand 9 (CXCL9)-3.10-1.12—
Chemokine (C-X-C motif) ligand 10 (CXCL10)-2.60-1.10—
Interferon (IFN)-γ-1.49-1.097—
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.

Treatment emergent adverse events (TEAEs) were defined as any AEs with onset date on or after the first study treatment dosing.

Time frame:
Between baseline and Week 12
Reported as:
Number · events
Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.
eventsDelgocitinib - DelgocitinibPlacebo - DelgocitinibNo Treatment
Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.49—

Adverse events

Collected over Baseline and week 12. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delgocitinib - Delgocitinib0/15 (0%)0/15 (0%)6/15 (40%)
Placebo - Delgocitinib0/15 (0%)0/15 (0%)10/15 (66.7%)
No Treatment———
Most frequent other events
Showing 10 of 18
Most frequent other events
EventDelgocitinib - DelgocitinibPlacebo - DelgocitinibNo Treatment
COVID-19Infections and infestations1/157/15—
PainGeneral disorders1/150/15—
PneumoniaInfections and infestations0/151/15—
Upper respiratory tract infectionInfections and infestations0/151/15—
Arthropod biteInjury, poisoning and procedural complications1/150/15—
Incision site rashInjury, poisoning and procedural complications1/150/15—
Procedural painInjury, poisoning and procedural complications1/150/15—
Antinuclear antibody positiveInvestigations0/151/15—
HyperlipidaemiaMetabolism and nutrition disorders0/151/15—
HyponatraemiaMetabolism and nutrition disorders1/150/15—

Baseline characteristics

Age, Continuous
Age, Continuous(years)Delgocitinib - DelgocitinibPlacebo - DelgocitinibNo TreatmentTotal
Mean66.2 ± 6.8262.6 ± 12.6467.4 ± 9.8164.8 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Delgocitinib - DelgocitinibPlacebo - DelgocitinibNo TreatmentTotal
Female1515535
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delgocitinib - DelgocitinibPlacebo - DelgocitinibNo TreatmentTotal
Hispanic or Latino2002
Not Hispanic or Latino1315533
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Delgocitinib - DelgocitinibPlacebo - DelgocitinibNo TreatmentTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1415534
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Delgocitinib - DelgocitinibPlacebo - DelgocitinibNo TreatmentTotal
United States1515535
Height (cm)
Height (cm)(units on a scale)Delgocitinib - DelgocitinibPlacebo - DelgocitinibNo TreatmentTotal
Mean163.34 ± 7.557162.49 ± 6.970165.20 ± 8.415163.24 ± 7.257
Weight (kg)
Weight (kg)(units on a scale)Delgocitinib - DelgocitinibPlacebo - DelgocitinibNo TreatmentTotal
Mean68.41 ± 15.24575.41 ± 16.50372.40 ± 17.41871.98 ± 15.950
08

Study locations

1 site
  • LEO Investigational Site
    Burlington, Massachusetts 01805, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Feb 2023, 9 months.

Results were first posted in Feb 2025, 1 year 11 months after primary completion. A results delay was requested in Feb 2024.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2022
First posted
Apr 18, 2022
StartActual
Apr 19, 2022
Primary completionActual
Feb 13, 2023
CompletionActual
May 22, 2023
Results delay requested
Feb 12, 2024
Results first posted
Feb 7, 2025
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05332366
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Apr 18, 2022
Start date
Apr 19, 2022
Primary completion
Feb 13, 2023
Completion
May 22, 2023
Results posted
Feb 7, 2025
Last update
Mar 6, 2025

Study contacts

Translational Medical Leader
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion